" class="no-js "lang="en-US"> Patricia Françon - Medtech Alert
Tuesday, April 16, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Patricia Françon

Patricia Françon

About Patricia Françon

Experienced Head of Drug Development with a demonstrated history of working in the biotechnology industry. Skilled in Biotechnology, Research and Development (R&D), Life Sciences, and CRO/CMO Management. Strong Projet Management professional with more than 20 years experience in the biotechnology and pharmaceutical industry.

Related Story

Appointments

 Coave Therapeutics Strengthens Leadership Team with the Appointments of Thomas Blaettler MD as Chief Medical Officer and Patricia Françon PhD as Chief Operating Officer | Pharmtech Focus

Coave Therapeutics Strengthens Leadership Team with the Appointments of Thomas Blaettler MD as Chief Medical Officer and Patricia Françon PhD as Chief Operating Officer

November 15 2021

Coave Therapeutics (‘Coave‘), a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare […]